Latest Phenethylamines Stories

A study from Karolinska Institutet shows that a new drug for Huntington's disease - pridopidine or dopamine stabilizer ACR16 - might operate via previously unknown mechanisms of action. Researchers have found that at very low concentrations, ACR16 binds to the sigma-1 receptor, a protein in the brain important to neuronal function and survival. This new knowledge can be used to develop future treatments for schizophrenia, involuntary Parkinsonian tremors and neurodegenerative diseases....

Patients studied produced pictures, sculptures, novels and poetry Some Parkinson's Disease patients can suddenly become creative when they take dopamine therapy, producing pictures, sculptures, novels and poetry. But their new-found interests can become so overwhelming that they ignore other aspects of their everyday life, such as daily chores and social activities, according to research published in the March issue of the European Journal of Neurology. Italian researchers studied 36...

Another review by the Food and Drug Administration (FDA) for a new drug yesterday resulted in a 20-2 judgment in favor of allowing Qnexa to be placed on the market to combat obesity, reports Rita Rubin for WebMD Health News. Qnexa is a combination of two drugs that have long been on the market -- appetite suppressant phentermine and topiramate, which is used to treat seizures and migraines. Obesity specialists and patient advocates agree there is a huge need for obesity drugs to bridge...

SHIRLEY, N.Y., Feb. 22, 2012 /PRNewswire/ -- American Regent is conducting a nationwide voluntary recall to the Retail/Hospital level of the following product: Phenylephrine HCl Injection, USP, 1% (10mg/mL), 5 mL VialNDC # 0517-0405-25, Lot # 0693, Exp Date: October, 2012. PLEASE NOTE: This recall, initiated on February 22, 2012 to the Retail/Hospital Level, is for Lot # 0693 only. No other lots or sizes of Phenylephrine HCl Injection, USP are subject to this voluntary...

Cascade Study Raises Questions about Real Impact of Oregon's Prescription-Only Requirement PORTLAND, Ore., Feb. 21, 2012 /PRNewswire-USNewswire/ -- Cascade Policy Institute released a study today which found the 2005 Oregon law which restricts access to medicines containing pseudoephedrine (PSE) has not made the illegal drug methamphetamine harder to get or reduced the number of people using it. The Oregon law makes any medication containing PSE available only via prescription...

Mexican troops reportedly seized 15 tons of pure methamphetamine in the western state of Jalisco on Wednesday. The historic seizure was an amount equivalent to half of all meth seizures worldwide in 2009.  Experts say the haul could have supplied 13 million doses worth over $4 billion on U.S. streets. "This could potentially put a huge dent in the supply chain in the U.S," U.S. Drug Enforcement Administration (DEA) spokesman Rusty Payne said in a statement. "When we're taking this much...

Mark Twain said, "Giving up smoking is the easiest thing in the world. I know because I've done it thousands of times." Many smokers would agree that it's difficult to stay away from cigarettes. A new study in Biological Psychiatry this month now suggests that low dopamine levels that occur as a result of withdrawal from smoking actually promote the relapse to smoking. Dopamine is a brain chemical messenger that is critically important in reward and motivation. Some research suggests that...

A 7-decades mystery solved It has long been known that psychostimulant drugs have the paradoxical effect of reducing hyperactivity. [Psychostimulant drugs include methylphenidate – known by the trade names Ritalin, Concerta, and Methylin – and methamphetamine]. Since the mid-1950s, millions of children and adults have been prescribed stimulant medications to control attention deficit hyperactivity disorder (ADHD). But for more than seven decades, since the first experiment that gave an...

PHILADELPHIA, Feb. 7, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) as a maintenance treatment for adults with ADHD. The approval is based on results from a randomized withdrawal study designed to evaluate the efficacy of Vyvanse in adults (aged 18 to 55 years) who...

PHILADELPHIA, February 7, 2012 /PRNewswire/ -- Vyvanse (lisdexamfetamine dimesylate), an approved treatment forAttention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, is the first medication both proven to work and approved for maintenance treatment in adults with ADHD Shire plc [http://www.shire.com/shireplc/en/home ] (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug...